PMID- 27389084
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20221207
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 128
IP  - 6
DP  - 2016 Aug
TI  - Impact of lorcaserin on glycemic control in overweight and obese patients with 
      type 2 diabetes: analysis of week 52 responders and nonresponders.
PG  - 591-7
LID - 10.1080/00325481.2016.1208618 [doi]
AB  - OBJECTIVES: Treatment guidelines for type 2 diabetes mellitus (T2DM) suggest 
      weight loss as a means to maintain glycemic control. Lorcaserin has been approved 
      for chronic weight management in the United States as an adjunct to a 
      reduced-calorie diet and exercise, and the previous phase 3 Behavioral 
      Modification and Lorcaserin for Obesity and Overweight Management in Diabetes 
      Mellitus (BLOOM-DM) study has shown that, in addition to weight loss, lorcaserin 
      is associated with improvements in glycemic parameters. In this post hoc analysis 
      of the BLOOM-DM trial, the relationship between responder status (patients 
      achieving >/=5% weight loss at Week 52) and glycemic and cardiometabolic parameters 
      is evaluated. METHODS: Data are presented for patients receiving lorcaserin 10 mg 
      twice daily or placebo for 52 weeks. RESULTS: More than twice as many patients 
      receiving lorcaserin plus diet and exercise counseling were classified as Week 52 
      responders compared to those receiving diet and exercise counseling alone (37.5% 
      vs. 16.1%, respectively; p < 0.001), and lorcaserin Week 52 responders had 
      greater improvements vs. placebo Week 52 responders in FPG (-38.1 mg/dL vs. 
      -26.0 mg/dL) and HbA1c (-1.3% vs. -1.0%). Furthermore, more lorcaserin-treated 
      Week 52 responders decreased the number of concomitant oral antidiabetic 
      medications (OADs) used, and fewer increased the number of OADs used, compared to 
      placebo. Unexpectedly, lorcaserin Week 52 nonresponders also had substantial 
      reductions in glycemic levels, despite very modest weight loss. CONCLUSIONS: 
      These data support lorcaserin use in overweight and obese patients with T2DM to 
      promote weight loss and facilitate glycemic control. CLINICAL TRIAL REGISTRATION: 
      www.clinicaltrials.gov identifier is NCT00603291.
FAU - Pi-Sunyer, Xavier
AU  - Pi-Sunyer X
AD  - a Division of Endocrinology , Columbia University Medical Center , New York , NY 
      , USA.
FAU - Shanahan, William
AU  - Shanahan W
AD  - b Formerly of the division of Preclinical and Clinical Drug Development , Arena 
      Pharmaceuticals, Inc ., San Diego , CA , USA.
FAU - Fain, Randi
AU  - Fain R
AD  - c Formerly of the Global Neuroscience Business Unit, Eisai Inc ., Woodcliff Lake 
      , NJ , USA.
FAU - Ma, Tony
AU  - Ma T
AD  - c Formerly of the Global Neuroscience Business Unit, Eisai Inc ., Woodcliff Lake 
      , NJ , USA.
FAU - Garvey, W Timothy
AU  - Garvey WT
AD  - d Department of Nutrition Sciences , University of Alabama at Birmingham, and the 
      Birmingham VA Medical Center , Birmingham , AL , USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00603291
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160718
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Benzazepines)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 637E494O0Z (lorcaserin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Benzazepines/*therapeutic use
MH  - Blood Glucose
MH  - Body Mass Index
MH  - Counseling
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diet
MH  - Double-Blind Method
MH  - Exercise
MH  - Female
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Obesity/therapy
MH  - Overweight/*drug therapy/therapy
MH  - Racial Groups
MH  - Serotonin Receptor Agonists/*therapeutic use
MH  - Weight Loss/drug effects
MH  - Young Adult
OTO - NOTNLM
OT  - Obesity
OT  - diabetes mellitus
OT  - lorcaserin
OT  - overweight
OT  - weight loss
EDAT- 2016/07/09 06:00
MHDA- 2017/02/07 06:00
CRDT- 2016/07/09 06:00
PHST- 2016/07/09 06:00 [entrez]
PHST- 2016/07/09 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
AID - 10.1080/00325481.2016.1208618 [doi]
PST - ppublish
SO  - Postgrad Med. 2016 Aug;128(6):591-7. doi: 10.1080/00325481.2016.1208618. Epub 
      2016 Jul 18.